JPRN-UMIN000016754已完成未知
The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan. - The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy.
Saitama Medical Center, Saitama Medical University0 个研究点目标入组 50 人开始时间: 2015年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patient with a severe ketotic diabetic coma or precoma. 2)Patient with severe infectious disease, before and after operation, and a serious injury. 3)End-stage renal failure patients with severe renal impairment (eGFR <30mL / min) or during dialysis 4)A pregnant woman or woman who may be pregnant. 5)Patient with a past history of hypersensitivity for Ipragliflozin. 6)Patients who isn't obtained the consent in writing 7)Patient who is considered to be inappropriate by the chief physician.
研究者
相似试验
已完成
不适用
Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndromeType 2 diabetesJPRN-UMIN000045226Akishima Clinic16
尚未招募
Unknown
Influence of SGLT2 inhibitors on the efficiency of peritoneal dialysisChronic kidney disease under peritoneal dialysisJPRN-UMIN000049848International University of Health and Welfare10
尚未招募
Unknown
Observational Study of the effect of SGLT2 inhibitor on Glycemic Control Indicesdiabetes mellitusJPRN-UMIN000050228agoya University4,250
招募中
不适用
Influence of SGLT2 inhibitor on myocardial fatty acid metabolismtype 2 diabetesJPRN-jRCT1041190002Kumazaki Setsuo40
进行中（未招募）
1 期
The REFORM TrialType 2 diabetes and Heart FailureEUCTR2014-002742-42-GBniversity of Dundee/ NHS Tayside56